PMID- 36143789
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220928
IS  - 1996-1944 (Print)
IS  - 1996-1944 (Electronic)
IS  - 1996-1944 (Linking)
VI  - 15
IP  - 18
DP  - 2022 Sep 18
TI  - Charge-Convertible and Reduction-Sensitive Cholesterol-Containing Amphiphilic 
      Copolymers for Improved Doxorubicin Delivery.
LID - 10.3390/ma15186476 [doi]
LID - 6476
AB  - For achieving successful chemotherapy against cancer, designing biocompatible 
      drug delivery systems (DDSs) with long circulation times, high cellular 
      endocytosis efficiency, and targeted drug release is of upmost importance. 
      Herein, a well-defined PEG-b-P(MASSChol-co-MANBoc) block copolymer bearing 
      redox-sensitive cholesteryl-side group was prepared via reversible 
      addition-fragmentation chain transfer (RAFT) polymerization (with non-redox 
      PEG-b-P(MACCChol-co-MAN-DCA) as the reference), and 1,2-dicarboxylic-cyclohexene 
      acid (DCA) was then grafted onto the hydrophobic block to endow it with 
      charge-convertible characteristics under a tumor microenvironment. The 
      amphiphilic copolymer could be assembled into polymeric spherical micelles 
      (SSMCs) with polyethylene glycol (PEG) as the corona/shell, and anti-cancer drug 
      doxorubicin (DOX) was successfully encapsulated into the micellar core via strong 
      hydrophobic and electrostatic interactions. This nanocarrier showed high 
      stability in the physiological environment and demonstrated "smart" surface 
      charge conversion from negative to positive in the slightly acidic environment of 
      tumor tissues (pH 6.5~6.8), as determined by dynamic light scattering (DLS). 
      Moreover, the cleavage of a disulfide bond linking the cholesterol grafts under 
      an intracellular redox environment (10 mM GSH) resulted in micellar dissociation 
      and accelerated drug release, with the non-redox-responsive micelles (CCMCs) as 
      the control. Additionally, a cellular endocytosis and tumor proliferation 
      inhibition study against MCF-7 tumor cells demonstrated the enhanced endocytosis 
      and tumor cell inhibitory efficiency of dual-responsive SSMCs/DOX nanomedicines, 
      revealing potentials as multifunctional nanoplatforms for effective oncology 
      treatment.
FAU - Wang, Zhao
AU  - Wang Z
AUID- ORCID: 0000-0002-1792-9030
AD  - School of Material Engineering, Jinling Institute of Technology, Nanjing 211169, 
      China.
AD  - Nanjing Key Laboratory of Optometric Materials and Technology, Nanjing 211169, 
      China.
FAU - Guo, Xinyu
AU  - Guo X
AD  - School of Material Engineering, Jinling Institute of Technology, Nanjing 211169, 
      China.
AD  - Nanjing Key Laboratory of Optometric Materials and Technology, Nanjing 211169, 
      China.
FAU - Hao, Lingyun
AU  - Hao L
AD  - School of Material Engineering, Jinling Institute of Technology, Nanjing 211169, 
      China.
AD  - Nanjing Key Laboratory of Optometric Materials and Technology, Nanjing 211169, 
      China.
FAU - Zhang, Xiaojuan
AU  - Zhang X
AD  - School of Material Engineering, Jinling Institute of Technology, Nanjing 211169, 
      China.
AD  - Nanjing Key Laboratory of Optometric Materials and Technology, Nanjing 211169, 
      China.
FAU - Lin, Qing
AU  - Lin Q
AUID- ORCID: 0000-0002-8761-9468
AD  - School of Material Engineering, Jinling Institute of Technology, Nanjing 211169, 
      China.
AD  - Nanjing Key Laboratory of Optometric Materials and Technology, Nanjing 211169, 
      China.
FAU - Sheng, Ruilong
AU  - Sheng R
AUID- ORCID: 0000-0002-3303-3832
AD  - CQM-Centro de Quimica da Madeira, Campus da Penteada, Universidade da Madeira, 
      9000390 Funchal, Madeira, Portugal.
LA  - eng
GR  - BK20190113/Natural Science Foundation of Jiangsu Province/
GR  - jit-b-201828, jit-fhxm-202114/Jinling Institute of Technology/
GR  - 51902145/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20220918
PL  - Switzerland
TA  - Materials (Basel)
JT  - Materials (Basel, Switzerland)
JID - 101555929
PMC - PMC9504105
OTO - NOTNLM
OT  - charge-convertible
OT  - cholesterol
OT  - drug delivery
OT  - reduction-sensitive
COIS- The authors declare no conflict of interest.
EDAT- 2022/09/24 06:00
MHDA- 2022/09/24 06:01
PMCR- 2022/09/18
CRDT- 2022/09/23 01:32
PHST- 2022/07/18 00:00 [received]
PHST- 2022/09/06 00:00 [revised]
PHST- 2022/09/15 00:00 [accepted]
PHST- 2022/09/23 01:32 [entrez]
PHST- 2022/09/24 06:00 [pubmed]
PHST- 2022/09/24 06:01 [medline]
PHST- 2022/09/18 00:00 [pmc-release]
AID - ma15186476 [pii]
AID - materials-15-06476 [pii]
AID - 10.3390/ma15186476 [doi]
PST - epublish
SO  - Materials (Basel). 2022 Sep 18;15(18):6476. doi: 10.3390/ma15186476.